Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011

Takla, Anja; Böhmer, Merle M.; Klinc, Christina; Kurz, Norbert; Schaffer, Alice; Stich, Heribert; Stöcker, Petra; Wichmann, Ole; Koch, Judith

doi:10.4161/hv.26642

Cited by 17 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data do not enable us to estimate the number of secondary infections in Germany, but it raises concern. It might be speculated that although vaccination seems to protect well in a younger age (Takla et al, 2014), adolescents and young adults seem to be more prone to a SVF. This hypothesis is supported by the fact that the group most affected in our study comprised the 15 to 29 year-olds.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Laboratory-based investigation of suspected mumps cases submitted to the German National Reference Centre for Measles, Mumps, and Rubella, 2008 to 2013

Mankertz

Beutel²,

Schmidt

et al. 2015

International Journal of Medical Microbiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

“…Among the patients, 90% had received at least one dose of the MMR vaccine and transmission from vaccinated individuals with a secondary infection to close contacts was observed (Fanoy et al, 2011). These observations are puzzling since epidemiological studies demonstrated a vaccine efficacy of >91% (Takla et al, 2014;Deeks et al, 2011).…”

Section: Introductionmentioning

confidence: 86%

Laboratory-based investigation of suspected mumps cases submitted to the German National Reference Centre for Measles, Mumps, and Rubella, 2008 to 2013

Mankertz

Beutel²,

Schmidt

et al. 2015

International Journal of Medical Microbiology

View full text Add to dashboard Cite

“…20 In a smaller outbreak in Germany, VE was calculated as 91.9% for 2 vaccine doses in children (mean age: 9 y) and 50.0% for one dose in adults (mean age: 26 y). 21 This study assessed VE during a mumps outbreak, which is naturally an uncontrolled and unplanned phenomenon. The study has several potential limitations.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of a large mumps outbreak: Clinical severity, complications and association with vaccination status of mumps outbreak cases

Stein‐Zamir

Schroeder

Shoob

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In recent years, large mumps outbreaks, involving mainly adolescents and young adults, have re-emerged in several countries. We investigated a large mumps outbreak, evaluated the association between mumps clinical severity (complications, hospitalization) and vaccination status (number of previous measles, mumps and rubella -MMR vaccine doses), and assessed vaccine effectiveness. The first mumps cases emerged in an ultra-orthodox boys' school in Jerusalem and were epidemiologically linked to the mumps outbreak in New York. Overall, 3130 mumps cases were notified in the Jerusalem district during September 2009-August 2011 (median age 13y, 64% males). Most cases were reported from community clinics. Patients with systemic symptoms and/or complications (419, 13.4%) were either hospitalized (n D 79) or treated in an emergency medical center (n D 340). The main complications included orchitis (3.8% males> age 12y) and meningoencephalitis (0.5%). The mumps virus genotype was G5. The distribution of previous MMR vaccine doses (n D 0,1,2) was: 24.8%, 28.3% and 46.9%, respectively. The number of previous vaccine doses was inversely associated with clinical severity. Adjusted values for MMR vaccine effectiveness against complications were estimated as 52.1% (95% CI ¡4 ¡78%) for one vaccine dose and 62.7% (95% CI 25.7-81.3%) for 2 doses. The outbreak was characterized by predominance of male students; the majority of whom had been previously vaccinated. The reported complication rate was relatively low. Vaccination status was associated with age and disease severity. The combination of limited mumps vaccine effectiveness and the specific school setting (dense learning and living conditions) probably contributed to the disease spread.

show abstract

“…14 The incidence of mumps has largely decreased since MMR vaccines containing the JL strain started to be used in national immunization programs, even though small mumps outbreaks sporadically occurred among adolescents in the European Union and United States (US). 15,16 A safe MMR vaccine containing a mumps strain which shows high immunogenicity is expected in Japan. A major population of the JL strain was cloned as RIT4385.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial

Nakayama

Eda²,

Hirano³

et al. 2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Domestic measles, mumps, and rubella combined (MMR) vaccines were discontinued in 1993 in Japan because of the unexpected high incidence of aseptic meningitis. The introduction of an effective MMR vaccine with lower reactogenicity has been expected. A new MMR vaccine (JVC-001) was developed, using mumps RIT4385 strain in combination with Japanese measles AIK-C strain and rubella Takahashi strain (MR) vaccine. An open-label, randomized, phase I/II clinical study was conducted in 100 healthy Japanese children equally randomized to a JVC-001 group and an MR with monovalent mumps vaccine (Hoshino strain) group. Immunogenicity was assessed using a neutralization test (NT) for measles, hemagglutination inhibition (HI) test for rubella, and NT and enzyme-linked immune-sorbent assay (ELISA) for mumps strain with different genotypes (genotype A, B, D and G) on Day 0 and Day 42-56. Solicited and unsolicited adverse events (AEs) were recorded. Seroconversion rates of measles and rubella were both 100%. JVC-001 induced higher immunogenicity against mumps virus genotype G with seroconversion rate of 77.1% (95% confidence interval [CI]: 62.7-88.0%) compared to 65.3% (95% CI: 50.4-78.3%) in the control group. Geometric mean titer (GMT) was 12.5 (95% CI: 8.6-18.3) in the JVC-001 group and 7.1 (95% CI: 5.0-10.1) in the control group. JVC-001 also induced good immunogenicity against other genotypes (A, B and D). There was no apparent difference in the incidence of AEs between JVC-001 and the control groups. JVC-001 is safe and induces effective immunogenicity against measles, mumps, and rubella compared with the currently marketed vaccines in Japan.

show abstract

Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011

Cited by 17 publications

References 27 publications

Laboratory-based investigation of suspected mumps cases submitted to the German National Reference Centre for Measles, Mumps, and Rubella, 2008 to 2013

Laboratory-based investigation of suspected mumps cases submitted to the German National Reference Centre for Measles, Mumps, and Rubella, 2008 to 2013

Characteristics of a large mumps outbreak: Clinical severity, complications and association with vaccination status of mumps outbreak cases

Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial

Contact Info

Product

Resources

About